Alnylam Pharmaceuticals | ALNY - Ordinary Share Capital

Stock Price
286.98
Daily Change
-6.47 -2.20%
Monthly
-10.36%
Yearly
0.59%
Q2 Forecast
281.21

Alnylam Pharmaceuticals reported $133.44M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amgen USD 540M 1000K Mar/2026
Arrowhead Research USD 137.39M 1.69M Dec/2025
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Incyte USD 199.95M 1.49M Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Novartis USD 1.91B 10.64M Dec/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Takeda JPY 1.58B 241K Mar/2026
Tectonic Therapeutic USD 18.74M 25.03K Dec/2025
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026
Xencor USD 74.06M 2.19M Mar/2026